SCHEMBL3322476

SCHEMBL3322476

CCOC(=O)c1cc2c(-c3ccc(C(F)(F)F)cc3)nc(N)nc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 6/20 0.53
MAPT P10636 4/20 0.49
KDM4E B2RXH2 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
HSP90AA1 P07900 2/20 0.49
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
DHODH Q02127 1/20 0.46
MAPK14 Q16539 1/20 0.43
ALDH1A1 P00352 5/20 0.40
HSD17B10 Q99714 1/20 0.40
ADORA1 P30542 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 3/20 0.39
PKM P14618 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13109522 0.88 HSP90AB1 (0.55) HSP90AB1MAPTKDM4EMEN1KMT2A
SCHEMBL13109525 0.88 HSP90AB1 (0.57) HSP90AB1MAPTKDM4EMAPK14ALDH1A1
SCHEMBL3950227 0.87 HSP90AB1 (0.55) HSP90AB1MAPTKDM4EMEN1KMT2A
SCHEMBL17355415 0.87 HSP90AB1 (0.56) HSP90AB1MAPTKDM4EMAPK14ALDH1A1
SCHEMBL13109505 0.87 HSP90AB1 (0.48) HSP90AB1MAPTKDM4EMEN1KMT2A
SCHEMBL13109969 0.86 HSP90AB1 (0.70) HSP90AB1MAPTKMT2ADHODHALDH1A1
SCHEMBL3322113 0.86 HSP90AB1 (0.69) HSP90AB1MAPTKDM4EMEN1KMT2A
SCHEMBL13109527 0.85 HSP90AB1 (0.54) HSP90AB1MAPTKDM4EMEN1KMT2A
SCHEMBL13109596 0.85 HSP90AB1 (0.54) HSP90AB1MAPTKDM4EMEN1KMT2A
SCHEMBL13109516 0.85 HSP90AB1 (0.54) HSP90AB1MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675861-B1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS R&D LTD (GB) 2015-12-23 EP disclosed
EP-1675861-B1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS R&D LTD (GB) 2015-12-23 EP disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
EP-1675861-A1 PYRIMIDOTHIOPHENE COMPOUNDS Vernalis (Cambridge) Limited (GB) 2006-07-05 EP disclosed
WO-2005021552-A1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS (CAMBRIDGE) LTD (GB) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120767-A1 Pyrimidothiophene Compounds ALK, HSP90AA1, HSP90AB1 HSP90AB1 3/4885MAPT 3898/4885KDM4E 4373/4885
US-20070043044-A1 Pyrimidothiophene compounds ALK, HSP90AA1, HSP90AB1 HSP90AB1 3/4885MAPT 3666/4885KDM4E 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.